NEW YORK,
Jan. 21,
2025 /PRNewswire/ -- Baird Medical Investment
Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a
leader in minimally invasive Microwave Ablation (MWA) technology,
proudly announces that Dr. Emad
Kandil, Professor and Ellis Hanna Chair in Surgery at
Tulane University School of Medicine,
has reached a remarkable milestone of successfully completing 100
MWA procedures for thyroid nodules. This achievement underscores
both the growing adoption of MWA and the transformative potential
of the technology in treating thyroid conditions.
Dr. Kandil, a pioneering expert in thyroid
surgery and minimally invasive techniques, has been instrumental in
advancing MWA as a safe and effective alternative to traditional
thyroid surgery. His completion of 100 cases highlights the
precision, efficiency, and clinical value of MWA, offering patients
faster recovery times, reduced procedural risks, and improved
quality of life.
To honor this achievement, Baird Medical
presented Dr. Kandil with a Certificate of Excellence, recognizing
his leadership in advancing thyroid care and his dedication to
adopting cutting-edge solutions for better patient outcomes.
As MWA technology continues to evolve, Baird
Medical is committed to driving innovation and expanding access to
advanced thyroid care. Through ongoing collaboration with leading
physicians and investment in physician education, Baird aims to
deliver even greater value to the medical community and the
patients they serve.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave
ablation (MWA) technology, offering advanced treatment solutions
for conditions such as thyroid nodules, breast disease, uterine
fibroids, and liver cancer. A publicly traded company on NASDAQ,
Baird Medical is dedicated to enhancing patient care through
precision, efficiency, and safety in its innovative medical
devices. For more information, please visit
https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the United States Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts and
generally relate to future events or Baird Medical's future
financial or operational performance. In some cases, you can
identify forward-looking statements by terminology such as "may,"
"might," "will," "should," "expect," "intend," "plan,"
"anticipate," "believe," "estimate," "predict," "potential,"
"continue," or the negative of these terms or other similar
expressions.
These forward-looking statements are subject to
risks, uncertainties, and assumptions that could cause actual
results or outcomes to differ materially from those expressed or
implied. These statements are based on estimates and assumptions
that, while considered reasonable by Baird Medical and its
management, are inherently uncertain. Risks and uncertainties may
emerge over time, and it is not possible to anticipate all
potential factors that could affect Baird Medical's business and
financial performance.
Factors that could cause actual results to differ
materially include, but are not limited to: (1) the risk that Baird
Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in
economic, regulatory, or market conditions that impact Baird
Medical's operations; (3) the ability to realize anticipated
benefits from ongoing business initiatives or strategic
transactions; (4) regulatory developments and compliance with
applicable laws; (5) risks related to the development,
commercialization, and market acceptance of Baird Medical's
products; and (6) other risks and uncertainties detailed in Baird
Medical's filings with the SEC.
Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date they are made. Baird Medical undertakes no obligation to
update or revise forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. All forward-looking statements in this press release are
qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dr-emad-kandil-achieves-milestone-of-100-microwave-ablation-cases-in-thyroid-care-302355874.html
SOURCE BDMD
